U.S. psychedelic drugs market is projected to register a substantial CAGR of 16.3% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
U.S. Psychedelic Drugs Market, By Source (Synthetic, Natural), Type (Dissociatives, Empathogens, Serotonergic (Classical Psychedelic Drugs) ), Application (Narcolepsy, Treatment-Resistant Depression, Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder, Others), Route of Administration (Oral, Intranasal, Parenteral, Others), Drugs (Gamma Hydroxybutyric Acid (GHB), Ketamine, 3,4-Methylenedioxymethamphetamine (Ecstasy), Psilocybin), End User (Hospitals, Speciality Clinic, Research Organization, Others), Distribution Channel (Hospital Pharmacy, Compounding Pharmacy, Others) - Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of the U.S. psychedelic drugs market are:
- Growing acceptance of psychedelic drugs for treating depression
- Increasing prevalence of depression and mental disorders
Market Players:
The key market players for U.S. psychedelic drugs market are listed below:
- Johnson & Johnson Services, Inc.
- Jazz Pharmaceuticals, Inc.
- Celon Pharma SA
- COMPASS
- usonainstitute.org
- Develco pharma schweiz ag
- Doughlas pharmaceuticals limited
- NeuroRX, Inc.
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals, LLC.
- AVADEL PHARMACEUTICALS, PLC